Advertisement
Advertisement
U.S. Markets close in 3 hrs 4 mins
Advertisement
Advertisement
Advertisement
Advertisement

Relay Therapeutics, Inc. (RLAY)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
18.59+0.81 (+4.56%)
As of 12:55PM EST. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close17.78
Open17.49
Bid18.35 x 800
Ask18.39 x 900
Day's Range17.20 - 18.61
52 Week Range12.65 - 35.36
Volume284,890
Avg. Volume1,221,927
Market Cap2.009B
Beta (5Y Monthly)1.11
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Relay Therapeutics to Participate in Two Upcoming Investor Conferences

    CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in two fireside chats this month at the H.C. Wainwright 3rd Annual Precision Oncology Virtual Conference on Monday, November 14, 2022 at 10:00 a.m. ET and the Stifel 2022 Healthcare Conference on Wednesday, November 16, 2022, at 1:15 p.m. ET. Both the H.C. Wainwright 3rd Annual Precision Oncology Virtual Conference and the Stifel 2022 Healthcare Conference will be webcast live

  • GlobeNewswire

    Relay Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights

    Shared 88% overall response rate (ORR) from interim data of RLY-4008 in pan-FGFR treatment (FGFRi)-naïve FGFR2-fusion cholangiocarcinoma (CCA) patients treated at the pivotal dose at European Society for Medical Oncology (ESMO) Congress $1.1 billion in cash, cash equivalents and investments at the end of third quarter 2022 CAMBRIDGE, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- – Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery proc

  • GlobeNewswire

    Relay Therapeutics to Announce Third Quarter 2022 Financial Results and Corporate Highlights

    CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, plans to report third quarter 2022 financial results and corporate highlights after the close of market on Thursday, November 3, 2022. The company will not be conducting a teleconference in conjunction with its financial results press release. About Re

Advertisement
Advertisement